Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

evolus inc - EOLS

EOLS

Close Chg Chg %
4.31 -0.28 -6.50%

Closed Market

4.03

-0.28 (6.50%)

Volume: 838.33K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: evolus inc - EOLS

EOLS Key Data

Open

$4.13

 Day Range

3.99 - 4.16

52 Week Range

3.86 - 12.28

 Market Cap

$262.19M

Shares Outstanding

65.06M

 Public Float

49.83M

Beta

1.00

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.80

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.62M

  

EOLS Performance

1 Week
 
 0.50%
 
1 Month
 
 -27.12%
 
3 Months
 
 -40.03%
 
1 Year
 
 -62.30%
 
5 Years
 
 -67.99%
 

EOLS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About evolus inc - EOLS

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

EOLS At a Glance

Evolus, Inc.
520 Newport Center Drive
Newport Beach, California 92660
Phone 1-949-284-4555 Revenue 297.18M
Industry Pharmaceuticals: Major Net Income -51,641,000.00
Sector Health Technology 2025 Sales Growth 11.605%
Fiscal Year-end 12 / 2026 Employees 334
View SEC Filings

EOLS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.443
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -18.363
Enterprise Value to Sales 1.783
Total Debt to Enterprise Value 0.293

EOLS Efficiency

Revenue/Employee 889,748.503
Income Per Employee -154,613.772
Receivables Turnover 5.433
Total Asset Turnover 1.296

EOLS Liquidity

Current Ratio 1.898
Quick Ratio 1.54
Cash Ratio 0.715

EOLS Profitability

Gross Margin 64.865
Operating Margin -12.652
Pretax Margin -17.149
Net Margin -17.377
Return on Assets -22.529
Return on Equity N/A
Return on Total Capital -39.155
Return on Invested Capital -39.249

EOLS Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 117.519
Total Debt to Total Assets 68.622
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 115.602
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Evolus Inc - EOLS

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
148.62M 202.09M 266.27M 297.18M
Sales Growth
+49.10% +35.98% +31.76% +11.61%
Cost of Goods Sold (COGS) incl D&A
59.61M 66.69M 86.31M 104.41M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.50M 5.87M 6.02M 8.74M
Depreciation
1.15M 1.79M 1.92M 2.47M
Amortization of Intangibles
3.35M 4.07M 4.10M 6.27M
COGS Growth
+21.26% +11.88% +29.42% +20.97%
Gross Income
89.01M 135.39M 179.96M 192.76M
Gross Income Growth
+76.19% +52.12% +32.92% +7.11%
Gross Profit Margin
+59.89% +67.00% +67.59% +64.86%
2022 2023 2024 2025 5-year trend
SG&A Expense
148.58M 171.50M 207.20M 230.36M
Research & Development
6.74M 6.56M 9.17M 9.58M
Other SG&A
141.84M 164.94M 198.03M 220.79M
SGA Growth
+30.18% +15.42% +20.81% +11.18%
Other Operating Expense
- - - -
-
Unusual Expense
5.75M 13.13M 7.18M (4.94M)
EBIT after Unusual Expense
(65.33M) (49.23M) (34.41M) (32.66M)
Non Operating Income/Expense
110.00K 1.56M 3.39M 1.39M
Non-Operating Interest Income
119.00K 860.00K 3.26M 1.93M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.10M 13.83M 18.73M 19.69M
Interest Expense Growth
+551.65% +52.05% +35.45% +5.12%
Gross Interest Expense
9.10M 13.83M 18.73M 19.69M
Interest Capitalized
- - - -
-
Pretax Income
(74.32M) (61.51M) (49.76M) (50.96M)
Pretax Income Growth
-58.91% +17.23% +19.11% -2.43%
Pretax Margin
-50.01% -30.44% -18.69% -17.15%
Income Tax
95.00K 176.00K 664.00K 677.00K
Income Tax - Current - Domestic
113.00K 138.00K 279.00K 90.00K
Income Tax - Current - Foreign
- 33.00K 406.00K 566.00K
Income Tax - Deferred - Domestic
(18.00K) 5.00K (21.00K) 21.00K
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(74.41M) (61.69M) (50.42M) (51.64M)
Minority Interest Expense
- - - -
-
Net Income
(74.41M) (61.69M) (50.42M) (51.64M)
Net Income Growth
-58.97% +17.10% +18.26% -2.42%
Net Margin Growth
-50.07% -30.52% -18.94% -17.38%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(74.41M) (61.69M) (50.42M) (51.64M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(74.41M) (61.69M) (50.42M) (51.64M)
EPS (Basic)
-1.3272 -1.0837 -0.813 -0.801
EPS (Basic) Growth
-41.12% +18.35% +24.98% +1.48%
Basic Shares Outstanding
56.07M 56.92M 62.02M 64.47M
EPS (Diluted)
-1.3272 -1.0837 -0.813 -0.801
EPS (Diluted) Growth
-41.12% +18.35% +24.98% +1.48%
Diluted Shares Outstanding
56.07M 56.92M 62.02M 64.47M
EBITDA
(55.08M) (30.24M) (21.21M) (28.86M)
EBITDA Growth
+3.88% +45.10% +29.84% -36.02%
EBITDA Margin
-37.06% -14.96% -7.97% -9.71%

Snapshot

Average Recommendation BUY Average Target Price 14.667
Number of Ratings 7 Current Quarters Estimate -0.042
FY Report Date 06 / 2026 Current Year's Estimate -0.16
Last Quarter’s Earnings -0.12 Median PE on CY Estimate N/A
Year Ago Earnings -0.439 Next Fiscal Year Estimate 0.203
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate -0.04 -0.04 -0.16 0.20
High Estimates 0.01 0.06 0.10 0.49
Low Estimate -0.07 -0.11 -0.54 -0.14
Coefficient of Variance -71.48 -177.96 -134.80 102.86

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Evolus Inc - EOLS

Date Name Shares Transaction Value
Feb 20, 2026 David Neil Gill Director 86,887 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Rui Avelar See Remarks 451,734 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Rui Avelar See Remarks 94,913 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Rui Avelar See Remarks 138,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Albert George White Director 95,937 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Vikram Malik Director 321,109 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Karah Parschauer Director 77,742 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 David Moatazedi See Remarks; Director 667,600 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 David Moatazedi See Remarks; Director 626,424 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 David Moatazedi See Remarks; Director 457,541 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Brady Stewart Director 134,188 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Tatjana Mitchell Chief Financial Officer 226,092 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Tatjana Mitchell Chief Financial Officer 121,489 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2026 Tatjana Mitchell Chief Financial Officer 177,471 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Evolus Inc in the News